Hydrofluoroalkane-Beclomethasone Dipropionate Effectively Improves Airway Eosinophilic Inflammation Including the Distal Airways of Patients with Mild to Moderate Persistent Asthma as Compared with Fluticasone Propionate in a Randomized Open Double-Cross Study  by Ohbayashi, Hiroyuki & Adachi, Mitsuru
Allergology International Vol 57, No3, 2008 www.jsaweb.jp 231
Hydrofluoroalkane-Beclomethasone
Dipropionate Effectively Improves
Airway Eosinophilic Inflammation
Including the Distal Airways of
Patients with Mild to Moderate
Persistent Asthma as Compared
with Fluticasone Propionate in a
Randomized Open Double-Cross
Study
Hiroyuki Ohbayashi1,2 and Mitsuru Adachi2
ABSTRACT
Background: To evaluate whether hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) controls
eosinophilic inflammation, including that in the distal airways, more effectively than fluticasone propionate (FP)
Diskus®.
Methods: Fifty patients with well-controlled mild to moderate persistent asthma using FP for more than 6
months were randomly assigned to FP and HFA-BDP groups, and the treatment regimens of the two groups
were switched twice between FP and HFA-BDP in a double cross-over manner at 3-month intervals after 2-
week washout periods. Evidence of eosinophilic inflammation in blood and induced sputum samples was as-
sessed, together with pulmonary function testing and an Asthma-related Quality of Life Questionnaire (AQLQ)
survey after each treatment period.
Results: The peripheral blood differential eosinophil count and sputum levels of eosinophil cationic protein
(ECP) showed reciprocal changes during the study periods in both groups. The blood differential eosinophil
count was significantly lower during the HFA-BDP than during the FP treatment period in both the FP (p =
0.004) and the HFA-BDP (p = 0.020) group. The late-phase induced sputum ECP level was significantly de-
creased during the HFA-BDP treatment period in both the FP (p = 0.016) and the HFA-BDP group (p = 0.023).
The significant elevation of surfactant protein D values in the late-phase sputum observed in both groups indi-
cated that late-phase sputum was obtained mainly from proximal peripheral airways. Both symptom and activity
limitation domains of the AQLQ in the HFA-BDP group significantly increased after switching from FP to HFA-
BDP. There were no significant changes in pulmonary function indices in either group at any time during the
study.
Conclusions: HFA-BDP improved residual eosinophilic inflammation in asthmatic airways, including distal
airways, more effectively than FP.
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INTRODUCTION
Eosinophilic inflammation in bronchial asthma is now
known to frequently involve even the small airways
and alveoli, as well as more distal bronchioles.1,2 It is,
therefore, important in asthma therapy to choose
drugs with adequate delivery to the distal airways, in
order to optimize the control of asthma and prevent
progression of airway remodeling. However, the fol-
lowing three critical clinical questions must first be
addressed. First, can we obtain effective control of
asthmatic inflammation in both central and peripheral
airways (<2 mm diameter) using inhaled corticoster-
oids, the gold standard for asthma therapy? Second,
using the same pharmacologically effective doses of
various types of inhaled corticosteroid (ICS), can we
expect an equal degree of anti-inflammatory effects in
the peripheral airways? Third, can ordinary clinical
examinations such as pulmonary function tests di-
rectly describe the status of inflammation in the pe-
ripheral airways and be utilized for evaluating the
therapeutic efficacies of drugs against peripheral in-
flammation?
To answer the above questions, we previously per-
formed two clinical studies. In the first, we confirmed
that 85 patients with stable mild to moderate persis-
tent asthma who had used the dry powder- type in-
haled steroid (DPI) for at least 6 months consistently
maintained good asthma control, based on routine
clinical examinations, such as pulmonary function
tests.3 Nevertheless, increased numbers of eosino-
phils were detected in 30―40% of late-phase induced
sputum samples from these patients, and this was ac-
companied by significantly increased sputum eosino-
phil cationic protein (ECP) levels.3 Most of the resid-
ual eosinophilic inflammation was ameliorated by
switching treatment from the DPI to hydrofluoral-
kane-134a beclomethasone dipropionate (HFA-BDP)
extra-fine aerosol therapy for 4 weeks.3 In our other
study, during a one-year observation period after
changing from DPI to HFA-BDP, we found virtually
no increases in either eosinophil counts or the ECP
levels in late-phase induced sputum.4 These results
raised three possibilities for approaching the residual
inflammation in the distal airways. First, even in pa-
tients on regular long-term treatment with DPIs in
whom stable daily control has apparently been main-
tained, the possibility of residual eosinophilic inflam-
mation existing in some of the distal airways must be
suspected. Second, routine examinations, such as
pulmonary function tests, are of limited value for di-
rectly evaluating changes in the distal airways, and
other methods must be developed. Third, optimal de-
livery to peripheral airways is obtained with HFA-
BDP, the aerosolized ultra-fine particles of which are
1.1 μm in diameter on average.5,6 This ICS may be a
good candidate for treating residual eosinophilic in-
flammation in the distal airways. Accordingly, we de-
cided to revisit the above questions using a stringent
study design. The aim of this study was to determine
whether HFA-BDP is more effective for controlling
eosinophilic inflammation in asthmatic airways, in-
cluding that in distal airways, than the FP Diskus®.
METHODS
SUBJECTS
The study was approved by the ethics committees of
Showa University (IRB approval No. 326) and Tohno-
Kousei hospital (IRB approval No. 8), and all patients
gave written informed consent. The study subjects
were 50 patients with mild to moderate persistent
asthma (classified according to the Global Initiative
on Asthma (GINA) guidelines)7 stably controlled
with the FP Diskus®, with good compliance and ad-
herence to treatment for more than 6 months. We ex-
cluded patients from the study who met the following
exclusion criteria: 1) daily oral steroid use, 2) under-
lying chronic obstructive pulmonary disease (COPD)
or other chronic respiratory diseases, 3) severe he-
patic or renal disease, heart failure, hematologic dis-
eases or other grave complications, 4) taking medica-
tion for chronic respiratory infectious diseases, and
5) history of poor drug compliance. Before enroll-
ment in the study, the clinical significance and pur-
pose of the study, and the possible disadvantages of
participation associated with switching inhaled corti-
costeroids twice in a double cross-over manner, were
explained in detail to each patient. After obtaining
written informed consent from each participant, they
were randomly divided into two groups: the “FP
Diskus® continuation” group (hereinafter, FP Dis-
kus® group) and the “switch to HFA-BDP” group
(hereinafter, HFA-BDP group). Patient characteris-
tics are presented in Table 1. The dosage of HFA-
BDP in the HFA-BDP group was set to be equivalent
to that of the FP used previously. Only three types of
medications, namely, long-acting beta2-agonists, leu-
kotriene receptor antagonists andor theophylline,
used before the study, were allowed as concurrent
drugs during the study, with the doses of these drugs
being kept constant throughout the study periods.
This study was carried out in accordance with the
principles embodied in the Helsinki Declaration of
1995 (as revised in Edinburgh 2000).
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Fig. 1 Study protocols.
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Table 1 Patient characteristics
Statistical analysisHFA-BDP groupFP group
2425Number of patients
p＝0.14817/712/13Gender (male/female)
p＝0.12467.9±13.161.0±17.4Mean age (years)
p＝0.61249.1±40.942.8±45.0Duration of asthma (months)
p＝0.496  4/20 7/18Atopic type/non-atopic type
p＝0.3141/10/130/7/18Smoker/ex-smoker/non-smoker
p＝0.8759/11/197/12/18Other concurently administered medications
(LABA/LTRA/theophyline)
Abbreviations: FP, Fluticasone Propionate DiskusⓇ; HFA-BDP, hydrofluoroalkane-beclomethasone dipropionate; LABA, long-acting 
beta2-adrenergic agonists; LTRA, leukotriene receptor antagonist.
STUDY PROTOCOL AND METHODS
The study protocol was divided into two stages (Fig.
1). During the 1st stage, we used the same design as
in our previous study.3 The peripheral blood differen-
tial eosinophil count and serum cortisol, as well as
the ECP levels in induced sputum samples, were ex-
amined before and three months after the start of the
study. Sputum was induced by having the subject in-
hale 10% hypertonic saline for 15 minutes, and all in-
duced sputum samples were sequentially collected
over 30 minutes. We regarded the first induced spu-
tum samples during 15 minutes of hypertonic saline
inhalation as early-phase samples, while those finally
collected after the inhalation period were taken as
late-phase samples. After saliva removal, the samples
were diluted five-fold with saline, stirred on a Vortex
mixer for one minute, and centrifuged at 4,000 G for
30 minutes at 4℃. The supernatant was collected,
mixed with a 1 mgmL solution of protamine sulfate
in 0.01 N hydrochloric acid at a ratio of 9 : 1, and
stored frozen at −70℃. The sputum ECP level was
measured using an ECP FEIA kit (Pharmacia & Up-
john Diagnostics AS, Uppsala, Sweden). The sputum
surfactant protein (SP)-D level was measured using
an SPD ELISA kit (Yamasa Co. Ltd. Chiba, Japan).
Various pulmonary function indices were measured
using a pulmonary function test apparatus (SP-750,
Fukuda Electronics, Tokyo, Japan). We also adminis-
tered the health-related Quality of Life (QOL) ques-
tionnaire developed by Juniper (Asthma-related Qual-
ity of Life Questionnaire; AQLQ)8 to all participants
before and at three months after the enrollment. Ap-
propriate permission to use the questionnaire was ob-
tained prior to starting the study.
Before starting the 2nd stage of the parallel-group
and double cross-over study, there was a two-week
washout period (Fig. 1). After the first cross-over pe-
riod of three months and another washout period of
two weeks, the ICS was again switched to the original
ICS which had been assigned at the time of enroll-
ment in the study and the same parameters as de-
scribed above for the first stage were examined. Each
parameter was examined at 3 months after each
switch, and other medications except for the ICS were
continued to be used during each washout period.
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Table 2 Changes in (A) percentages of plasma and sputum eosinophils and sputum ECP, (B) AQLQ scores and (C) pulmo-
nary function during the first 3 months (first stage) of the study
(A) Percentages of plasma and sputum eosinophil and sputum ECP
Statistical 
diferences 
between the 
two groups 
(p value)
Statistical 
significance
(p value)
3 months 
laterBefore
HFA-BDP 
group
Statistical 
significance
(p value)
3 months 
laterBeforeFP group
0.039 (＊)0.028 (＊)2.5±2.33.6±2.4
Plasma 
eosinophils
(%)
(n＝24)
0.5263.6±3.03.8±2.7
Plasma 
eosinophils
(%) 
(n＝25)
0.2540.54115.2±13.613.3±6.0 
Serum cortisol 
(μg/dL) 
(n＝24)
0.08815.7±7.1 13.9±5.8 
Serum cortisol 
(μg/dL)
(n＝25)
0.5730.0917.3±3.610.7±6.1 
Sputum 
eosinophils
(%) 
(Early phase) 
(n＝13)
0.67911.0±6.2 9.7±8.8
Sputum 
eosinophils
(%) 
(Early phase) 
(n＝13)
0.028 (＊)0.007 (＊＊)6.2±2.512.3±7.0 
Sputum 
eosinophils
(%)
(Late phase) 
(n＝13)
0.62611.6±6.6 12.8±11.7
Sputum 
eosinophils
(%)
 (Late phase)
 (n＝13)
0.7150.644246.7±305.8
306.2±
 426.8
Sputum ECP 
(Early phase) 
(n＝13)
0.626874.2±336.1
632.5±
1024.5
Sputum ECP 
(Early phase) 
(n＝13)
0.2820.044 (＊)156.3±149.7
1569.5± 
2278.0
Sputum ECP 
(Late phase) 
(n＝13)
0.9971737.0± 4659.3
1740.7± 
2261.3
Sputum ECP 
(Late phase)
 (n＝13)
(B) AQLQ scores (median (25 percentile―75 percentile)
Statistical 
diferences 
between the 
two groups 
(p value)
Statistical 
significance
(p value)
3 months 
laterBefore 
HFA-BDP
group 
(n＝24)
Statistical 
significance
(p value)
3 months 
laterBefore 
FP group
 (n＝25)
0.8830.033 (＊)6.42(5.46―6.67)
5.96
(5.33―6.67)Symptoms0.715
6.42
(5.58―6.92)
6.42 
(5.90―6.83)Symptoms
0.2820.036 (＊)5.50(4.94―6.50)
5.38
(4.69―5.88)
Activity
limitation0.232
5.88
(5.41―6.50)
5.63
(5.25―6.28)
Activity
limitation
0.9010.1276.10(5.30―6.60)
5.60
(5.20―6.70)
Emotional 
function0.712
6.40
(5.60―6.80)
6.40
(5.60―6.80)
Emotional 
function
0.6080.3076.00(5.13―6.75)
5.75
(5.25―6.88)
Exposure to 
environmental 
stimuli
0.9686.25(5.75―6.75)
6.25
(5.75―6.75)
Exposure to 
environmental 
stimuli
(C) Pulmonary function during the first 3 months (first stage) of the study
Statistical 
diferences 
between the 
two groups 
(p value)
Statistical 
significance
(p value)
3 months 
laterBefore
HFA-BDP
group (n＝24)
Statistical 
significance
(p value)
3 months 
laterBefore
FP group 
(n＝25)
0.5690.87796.7±18.596.4±18.9%VC0.45499.8±12.598.8±13.0%VC
0.4070.69390.1±17.591.0±20.3%FVC0.20396.4±13.393.6±14.4%FVC
0.6120.97494.2±25.894.3±26.7%FEV1.00.50496.8±30.595.7±29.6%FEV1.0
0.8680.48170.2±13.869.2±13.0FEV1.0%-G0.29674.4±13.175.8±13.3FEV1.0%-G
0.8160.76671.0±38.773.3±36.8MEFR%0.91776.5±27.076.1±28.5MEFR%
0.0800.24771.5±24.567.4±27.7PEF%0.19573.6±20.769.6±15.7PEF%
0.6000.1791.97±1.372.12±1.64FEF50(L/sec)0.1852.18±1.342.37±1.37
FEF50
(L/sec)
0.9210.3400.63±0.470.58±0.40FEF75 (L/sec)0.4180.74±0.500.80±0.49
FEF75
(L/sec)
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Table 3 Comparison of early phase and late phase sputum findings at the start of the study
HFA-BDP group (N＝13)FP group (N＝13)
73.70%63.60%Sputum induction rate
Late-phaseEarly-phaseLate-phaseEarly-phasePhase
1569.5.0±2278.0
(p＝0.078)306.2±426.8
1740.7±2261.3
(p＝0.086)632.5±1024.3ECP
 46.3±23.3
(p＝0.042)27.3±29.6
42.1±42.9
(p＝0.044)19.7±24.2 SPD
 12.3±7.0
(p＝0.548)10.7±6.1 
12.8±11.7
(p＝0.319)9.7±8.8 Eo%
Sputum induction rate: rates which induced sputum were obtained in the two phases.
STATISTICAL ANALYSIS
The significance level was set at 5%. The peripheral
blood differential eosinophil count, serum cortisol
level and the values of pulmonary function indices,
are presented as means ± SD, while sputum ECP lev-
els and the AQLQ scores are presented as means ±
SE and median values (25th―75th percentile), respec-
tively. The patient characteristics in the two ICS
groups shown in Figure 1 were analyzed using an un-
paired t test and Fisher’s exact probability test. Statis-
tical analyses of the time-course of changes in the pe-
ripheral blood differential eosinophil count, the in-
duced sputum ECP, pulmonary function values, and
the AQLQ scores were analyzed by the Kruskal-
Wallis method and the Wilcoxon signed-rank test
with Bonferroni’s correction. Statistical comparisons
between the two groups were made by the Friedman
test. Statistical analyses were carried out using JMP,
version 5.0.1a (SAS Institute Inc., Cary, NC, USA).
RESULTS
Soon after the start of the study, one elderly patient in
the HFA-BDP group dropped out due to the onset of
dementia.
RESULTS FROM THE FIRST STAGE OF THE
STUDY
The changes in various parameters during the 3-
month period of the first stage of the study are shown
in Table 2 (A)−(C). The peripheral blood differential
eosinophil count in the HFA-BDP group was signifi-
cantly decreased as compared with that in the FP
group (Table 2 (A)). The sputum eosinophil percent-
ages and ECP values in the late-phase samples were
also significantly decreased in the HFA-BDP group.
The scores for both symptom and activity limitation
domains of the AQLQ were also significantly im-
proved over the three months of the first stage (Table
2 (B)). On the other hand, there were no significant
changes in the various pulmonary function indices
(Table 2 (C)). Table 3 shows the comparison be-
tween early- and late-phase sputum samples. The spu-
tum SP-D levels in the late-phase sputum samples
were significantly higher than those in the early-
phase sputum samples in both groups. The sputum
eosinophil percentages and ECP values were also sig-
nificantly elevated in the late-phase samples at the
start of the study (Table 3).
RESULTS FROM THE SECOND STAGE OF THE
STUDY
The peripheral blood differential eosinophil count in
the FP group was significantly lower during the HFA-
BDP-assigned period than during the FP-assigned pe-
riod (Fig. 2). In contrast, in the HFA-BDP group, the
peripheral blood differential eosinophil count was sig-
nificantly elevated during the FP-assigned period.
The two graphs in Figure 2 show the reciprocal
changes in these two groups. The AQLQ scores for
both groups are shown in Figure 3. In the HFA-BDP
group, the scores in both symptom and activity limita-
tion domains significantly increased after the switch
(second cross-over) from FP to HFA-BDP. Figure 4
shows the sputum ECP levels over the double cross-
over study period in the two groups; the sputum ECP
levels also showed reciprocal changes in the two
groups. In particular, the ECP level in the late phase
sputum samples in the HFA-BDP group significantly
increased after the FP-assigned period as compared
with that after the other HFA-BDP-assigned period
(p = 0.012 and p = 0.023) (Fig. 4). There were no sig-
nificant changes between the two groups in the vari-
ous pulmonary function indices over the second stage
of the study (Table 4).
DISCUSSION
The results of this randomized double cross-over
study provide strong evidence that HFA-BDP is more
effective at controlling eosinophilic inflammation in
asthmatic airways, including that in the distal air-
ways, than the FP Diskus®.
During the first stage of the study, we reconfirmed
the results obtained in our previous study, as fol-
lows.3 Despite good and stable control of asthma be-
ing maintained with continuous FP administration for
at least 6 months, residual eosinophilic inflammation
Ohbayashi H et al.
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Fig. 2 Changes in peripheral blood eosinophil percentages during the 2nd stage of the 
study. Statistical significance: ＊P/2＜0.05 and ＊＊P/2＜0.01 compared with the periph-
eral blood diferential eosinophil count during the first cross-over stage．
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Fig. 3 AQLQ score changes in the FP and HFA-BDP groups during the 2nd stage of the study. Statistical 
significance: ＊P/2＜0.05 compared with the AQLQ scores during the first cross-over stage.
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in the asthmatic airways, including distal airways,
persisted (Table 2). Furthermore, significant im-
provement in this residual inflammation was ob-
served in the HFA-BDP group. Both the peripheral
blood differential eosinophil count and the scores in
two AQLQ domains, namely, symptoms and activity
limitation, also improved significantly in the HFA-
BDP group during this stage, accompanied by signifi-
cant improvements in the eosinophil percentages and
ECP levels in late-phase sputum samples (Table 2).
Although dose-related suppression of serum and
urine cortisol levels at higher doses has been re-
ported with HFA-BDP,9 we found no significant adre-
nal suppression at the conventional dose used in this
study. The reason why HFA-BDP could reduce the
peripheral blood eosinophil count with no adrenal
suppression was unclear. However, a small dose of in-
haled HFA-BDP may possibly go through the alveoli
HFA-BDP Improves Distal Airway Inflammation
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Fig. 4 Changes in sputum ECP levels during the 2nd stage of the study. Statistical significance: ＊＊P/2＜
0.01 compared with the sputum ECP levels during the first cross-over stage.
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into the circulation, which may result in obtaining
beneficial suppression of eosinophils in peripheral
blood.
During the second stage, we directly compared the
preventive effects on airway inflammation of two
types of ICS in a randomized double cross-over man-
ner. The results revealed inverse changes in the pe-
ripheral blood differential eosinophil count in both
groups (Fig. 2), suggesting that HFA-BDP has
greater efficacy against eosinophilic inflammation in
asthmatic airways. A previous study demonstrated
significantly greater reductions from baseline in
mean peripheral blood differential eosinophil counts
and serum ECP levels in patients treated with HFA-
BDP than in those receiving HFA-FP.10 Based on the
finding of a higher rate of deposition in the lungs of
radio-labeled HFA-BDP (53% ex-actuator) as com-
pared with CFC-FP (12 to 13%) or CFC-BDP (4%),11 it
is suggested that many HFA-BDP extra-fine particles
reach the peripheral airways, and some may even en-
ter the circulation via alveoli. During the second
stage, HFA-BDP significantly improved inflammation
in the distal airways, as reflected mainly by the re-
sults of analyzing the late-phase sputum samples
(Fig. 4). A randomized placebo-controlled study by
Hauber et al. showed that HFA-BDP reduced eosino-
philic inflammation and T helper 2-type cytokine ex-
pression in both early- and late-phase sputum sam-
ples, whereas budesonide did so only in the early-
phase samples.12 This also suggested the superiority
of HFA-BDP in terms of delivery into the distal air-
way. Herein, we obtained a significant decrease in the
AQLQ score in the FP group when the ICS was
changed from HFA-BDP to FP in the double cross-
over study (Fig. 3). These results may indicate a cor-
relation between improved QOL and reduced eosino-
philic inflammation with the use of HFA-BDP. On the
other hand, our results confirmed the lack of signifi-
cant changes in pulmonary function test parameters
during the second stage (Table 4). Other previous
studies also failed to detect any significant differences
in pulmonary function parameters, including daily
peak flow rates, between patients receiving HFA-BDP
versus FP at equivalent dose ratios.13-15 These obser-
vations indicated that pulmonary function parameters
may be of limited efficacy for recognizing inflamma-
tory changes in the distal airways. However, despite
the urgent need to devise simple and relatively non-
invasive means of detecting inflammation in the pe-
ripheral airways, no such methods have as yet been
Ohbayashi H et al.
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Table 4 Changes in pulomonary function during the 2nd stage of the study
Statistical 
significance 
between 
both groups 
(p value)
HFA-BDP GroupFP Group
Statistical 
significance
 (p value)
Double 
cross 3MCross 3M3M
Statistical 
significance 
(p value)
Double 
cross 3MCross 3M3M
0.2890.53797.2
±18.1
98.6
±18.8
96.7
±18.5
0.14899.5
±11.5
99.5
±12.5
99.8
±12.2
%VC
0.7810.33589.8
±20.7
92.4
±25.8
90.1
±17.5
0.11093.1
±12.7
94.3
±14.3
96.4
±13.3
%FVC
0.7210.80995.2
±28.1
94.1
±25.1
94.2
±25.8
0.20593.7
±24.4
95.4
±28.1
96.8
±30.5
%FEV1.0
0.5150.37069.0
±11.0
68.4
±12.7
70.2
±13.8
0.24075.9
±12.6
74.7
±11.5
74.4
±13.1
FEV1.0%-G
0.8990.48378.3
±39.8
76.1
±38.6
71.0
±38.7
0.50170.7
±31.5
68.7
±32.0
76.5
±27.0
MEFR%
0.4460.65369.5
±26.4
69.5
±23.8
71.5
±24.5
0.50271.6
±19.0
73.5
±20.2
73.6
±20.7
PEF%
0.5510.4311.85
±1.39
1.93
±1.36
1.97
±1.37
0.5092.2
±1.18
1.99
±1.09
2.18
±1.34
FEF50 
(L/sec)
0.3640.7080.55±0.41
0.53
±0.41
0.62
±0.470.849
0.77
±0.54
0.75
±0.53
0.74
±0.50
FEF75 
(L/sec)
established. A previous study by Fahy et al. found
that eosinophil percentages and ECP levels in in-
duced sputum samples from both patients with
asthma and healthy subjects were greater than those
in bronchoalveolar lavage fluids or bronchial wash-
ings, suggesting that analysis of induced sputum
samples may be useful for evaluating the condition of
peripheral airways.16 Furthermore, Gershman et al.
reported that sputum samples collected at least 12
minutes after the start of induction with 3% saline and
collected every four minutes during a 20-minute in-
duction contained significantly higher levels of sur-
factant protein A.17 These findings suggest that analy-
sis of late-phase induced sputum samples may more
clearly reflect the conditions of distal airways. In this
study, patients inhaled 10% hypertonic saline for 15
minutes, and the sputum specimens were sequen-
tially collected over a period of 30 minutes. As a re-
sult, the sputum levels of SP-D, secreted by alveolar
type II cells,18 were significantly elevated in the late-
phase induced sputum samples (Table 3), suggesting
that these samples were mainly from the proximal pe-
ripheral airways. Although we cannot be certain that
the method of sputum induction in this study obtains
samples optimally reflecting the condition of the pe-
ripheral airways, it is reasonable to assume that the
sputum collected more reliably reflects the condition
of the distal airways than that obtained with other
routine examinations. When counting the numbers of
eosinophils, while we found some squamous cells in
the early-phase sputum samples, marked elevation of
macrophage numbers was detected in the late-phase
ones. However, one of the greatest limitations of inha-
lational methods for sputum induction is that we can-
not consistently obtain both early- and late-phase spu-
tum samples of adequate quantity (induction rate, 60―
70%) at the same time during the same induction pro-
cedure.
In conclusion, this randomized double cross-over
study showed that HFA-BDP can control residual
eosinophilic inflammation in asthmatic airways, in-
cluding that in distal airways, more effectively than
FP. Routine pulmonary function test parameters are
of limited efficacy for recognizing inflammatory
changes in the distal airways, while sputum induction
with inhalation of 10% hypertonic saline for 15 min-
utes appears to be an easy, relatively non-invasive
method allowing selective analysis of secretions from
the distal airways.
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